The purpose of this study is to compare the single-dose pharmacokinetics (PK) of casdatifan 100 mg versus four 25 mg tablets under fasting conditions in healthy adult participants, and to evaluate the effect of food on the single-dose PK of casdatifan 100 mg administered as four 25 mg tablets in healthy adult participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
24
Administered as specified in the treatment arm
Research Site
Tempe, Arizona, United States
Maximum observed concentration for casdatifan
Time frame: Up to 168 hours post each dose
Area under the concentration-time curve for casdatifan
Time frame: Up to 168 hours post each dose
Time to reach Cmax (Tmax) for casdatifan
Time frame: Up to 168 hours post each dose
Lag time (Tlag) for casdatifan
Time frame: Up to 168 hours post each dose
Apparent first-order terminal elimination rate constant (Kel) for casdatifan
Time frame: Up to 168 hours post each dose
Percent of AUC0-inf extrapolated for casdatifan
Time frame: Up to 168 hours post each dose
Apparent first-order terminal elimination half-life (t½) for casdatifan
Time frame: Up to 168 hours post each dose
Apparent total clearance after extravascular (oral) administration (CL/F) for casdatifan
Time frame: Up to 168 hours post each dose
Apparent total clearance after extravascular (oral) administration (Vz/F) for casdatifan
Time frame: Up to 168 hours post each dose
Number of participants experiencing Adverse Events (AEs)
Time frame: Up to 43 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.